FIND in the news
Links to news items can only be guaranteed on date of publication.
The first study, led in London by the Hospital for Tropical Diseases (HTD), the London School of Hygiene & Tropical Medicine and the Foundation for Innovative New Diagnostics (FIND), compared LAMP to existing laboratory diagnostic methods on 705 blood samples of suspected imported malaria cases in the UK.
A number of researchers and companies are focused on developing new diagnostics for the developing world that address malaria and other infectious diseases. Last month the U.K.'s Lumora, a molecular diagnostic company, disclosed it would work with the Foundation for Innovative New Diagnostics to develop a malaria assay. The technology at play will also be able to test for a broader menu of diseases, including HIV.
Dr David Bell from the Foundation for Innovative New Diagnostics (FIND) said: “Most people who die of infectious diseases in malaria affected countries do so because they are given the wrong medicine, or the right medicine too late. Senegal saved over a million dollars-worth of antimalarial drugs in the first few years after introducing the tests.”
MBio Diagnostics, Inc., a medical device company, and Foundation for Innovative New Diagnostics, or FIND, have announced the completion of Phase I of tuberculosis, or TB, serology feasibility program.
They're focused on developing such a diagnostic that could screen for parasitemia malaria infections that would otherwise be hidden or at very low levels. One recently unveiled test accomplishes this--a collaboration between the Foundation for Innovative New Diagnostics and Eiken Chemical in Japan, the announcement notes.
Cambridge, UK, Wednesday 17 April 2013 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has partnered with The Foundation for Innovative New Diagnostics (FIND) to develop a rapid, high-throughput malaria diagnostic assay for screening patients in the developing world.
Out of 27 Gene Xpert MTB/RIF machines currently in use in Viet Nam, 17 were funded by TB CARE I, 5 by TB REACH, 2 by Canadian International Development Agency (CIDA), 1 by Oxford University Clinical Research Unit (OUCRU), 1 by PANTHER, 1 by Foundation for Innovative New Diagnostics (FIND).
An interview with Dr. Madhukar Pai reporting on promising recent developments in the global efforts to eliminate TB. For the first time, a rapid, cartridge-based, automated molecular test—the Xpert MTB/RIF test—is being scaled up for diagnosis of mycobacterium tuberculosis and detection of drug-resistance to rifampicin in more than 20 countries. The Xpert MTB/RIF technology was developed with the support of the Foundation for Innovative New Diagnostics (FIND) and endorsed by the World Health Organization in 2010. There is good evidence supporting its high accuracy. Since then, over 1,900,000 Xpert MTB/RIF cartridges have been procured worldwide in the public sector in 77 of the 145 countries eligible for concessional pricing of $9.98 per cartridge.
Zeiss is itself a member of WHO’s Stop TB initiative, which was founded in 2006 with the aim of eliminating the disease by 2050. The Germany-headquartered company developed Primo Star iLED with the Swiss Foundation for Innovative New Diagnostics (FIND), and the microscope is made available to health facilities in the worst-hit countries at a greatly reduced price.
Dr. Rahul Narang of Foundation for Innovative New Diagnostics (FIND) explained about LPA and conducted a demonstration which was relayed live on CCTV from the CDST Lab.
Researchers, from the Cochrane Infectious Diseases Group, McGill University and the Foundation for Innovative New Diagnostics (FIND), analysed data from 18 studies, spread over 27 distinct centres, and involving a total of 7,816 adults supposed to be having pulmonary TB or multidrug-resistant TB (MDR-TB) -- with or without HIV infection -- with a view to assess the diagnostic accuracy of the Xpert ® MTB/RIF test -- a rapid, automated diagnostic test endorsed by the World Health Organization (WHO) in 2010 that simultaneously detects TB and resistance to rifampicin, as an indicator of multidrug-resistance.
Recognizing this need, the Foundation for Innovative New Diagnostics (FIND) was created in 2003 as a Product Development Partnership (PDP). Its mission is to develop and deliver innovative and affordable POC diagnostic tests for poverty-associated diseases, such as tuberculosis, malaria, sleeping sickness, leishmaniasis, and Chagas disease.
The Foundation for Innovative New Diagnostics (FIND), which is driving the development and early implementation of diagnostic tests for tuberculosis (TB), malaria and other diseases of the developing world, is extending its existing development partnership with 42 Technology (42T).